Time-dependent effects of striatal interleukin-2 on open field behaviour in rats

Journal of Neuroimmunology

Volumn 208, Issue 1-2, 2009, Pages 10-18

  Karrenbauer, Britta D ^a   Ho, Ying Jui ^b   Ludwig, Verena ^a   Löhn, Jeanette ^a   Spanagel, Rainer ^c   Schwarting, Rainer K W ^a   Pawlak, Cornelius R ^c  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^c CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

Author keywords

Anxiety; Aversion; Avoidance; Basal ganglia; Cytokines; Microinjection

Indexed keywords

CYTOKINE; INTERLEUKIN 2; MESSENGER RNA; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANXIETY; ARTICLE; AVOIDANCE BEHAVIOR; BRAIN TISSUE; COMPARATIVE STUDY; CONTROLLED STUDY; CORPUS STRIATUM; DOSE RESPONSE; EMOTIONALITY; EXPOSURE; GENE EXPRESSION; GENE REPRESSION; INJECTION; LOCOMOTION; MALE; MAZE TEST; MOTIVATION; NONHUMAN; OPEN FIELD BEHAVIOR; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROACTIVE INHIBITION; RAT; STRIATE CORTEX; TIME; TRANQUILIZING ACTIVITY;

ANIMALS; ANXIETY; AVOIDANCE LEARNING; CORPUS STRIATUM; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; EXPLORATORY BEHAVIOR; INTERLEUKIN-2; MALE; MOTOR ACTIVITY; RATS; RATS, WISTAR; TIME FACTORS;

EID: 62549147491     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2008.12.003     Document Type: Article

References (65)

1. Anisman H., and Merali Z. Anhedonic and anxiogenic effects of cytokine exposure. Adv. Exp. Med. Biol. 461 (1999) 199-233
2. Anisman H., Kokkinidis L., and Merali Z. Interleukin-2 decreases accumbal dopamine efflux and responding for rewarding lateral hypothalamic stimulation. Brain Res. 731 (1996) 1-11
3. Anisman H., Kokkinidis L., Borowski T., and Merali Z. Differential effects of interleukin (IL)- 1beta, IL-2 and IL-6 on responding for rewarding lateral hypothalamic stimulation. Brain Res. 779 (1998) 177-187
4. Anisman H., Kokkinidis L., and Merali Z. Further evidence for the depressive effects of cytokines: anhedonia and neurochemical changes. Brain Behav. Immun. 16 (2002) 544-556
5. Anisman H., Merali Z., Poulter M.O., and Hayley S. Cytokines as a precipitant of depressive illness: animal and human studies. Curr. Pharm. Design 11 (2005) 963-972
6. Bhatt S., and Siegel A. Potentiating role of interleukin 2 (IL-2) receptors in the midbrain periaqueductal gray (PAG) upon defensive rage behavior in the cat: role of neurokinin K(1) receptors. Behav. Brain Res. 167 (2006) 251-260
7. Booij L., Van der Does A.J.W., and Riedel W.J. Monoamine deletion in psychiatric and healthy populations: review. Mol. Psychiatry 8 (2003) 951-973
8. Cahill L., and McGaugh J.L. Mechanisms of emotional arousal and lasting declarative memory. Trends Neurosci. 21 (1998) 294-299
9. Capuron L., Ravaud A., and Dantzer R. Early depressive symptoms in cancer patients receiving interleukin 2 and/or interferon Alfa-2b therapy. J. Clin. Oncol. 18 (2000) 2143-2151
10. Capuron L., Ravaud A., Neveu P.J., Miller A.H., Maes M., and Dantzer R. Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol. Psychiatry 7 (2002) 468-473
11. Capuron L., Pagnoni G., Demetrashvili M.F., Lawson D.H., Fornwalt F.B., Woolwine B., Berns G.S., Nemeroff C.B., and Miller A.H. Basal ganglia hypermetabolism and symptoms of fatigue during interferon-α therapy. Neuropsychopharmacology 32 (2007) 2384-2392
12. Clement Y., and Chapouthier G. Biological bases of anxiety. Neurosci. Biobehav. Rev. 22 (1998) 623-633
13. Connor T.J., Song C., Leonard B.E., Merali Z., and Anisman H. An assessment of the effects of central interleukin-1beta, -2, -6, and tumor necrosis factor-alpha administration on some behavioural, neurochemical, endocrine and immune parameters in the rat. Neuroscience 84 (1998) 923-933
14. Dantzer R., Wollman E., Vitkovic L., and Yirmiya R. Cytokines and depression: fortuitous or causative association?. Mol. Psychiatry 4 (1999) 328-332
15. De Sarro G.B., Masuda Y., Asciotti C., Audino M.G., and Nisticó G. Behavioural and ECoG spectrum changes induced by intracerebral infusion of interferons and interleukin 2 in rats are antagonized by naloxone. Neuropharmacology 29 (1990) 167-179
16. Ferreira T.L., Moreira K.M., Ikeda D.C., Bueno O.F.A., and Oliveira M.G.M. Effects of dorsal striatum lesions in tone fear conditioning and contextual fear conditioning. Brain Res. 987 (2003) 17-24
17. Gaffen S.L., and Liu K.D. Overview of interleukin-2 function, production and clinical applications. Cytokine 28 (2004) 109-123
18. Gironi Carnevale U.A., Vitullo E., and Sadile A.G. Post-trial NMDA receptor allosteric blockade differentially influences habituation of behavioral responses to novelty in the rat. Behav. Brain Res. 39 (1990) 187-195
19. Grillner S., Wallén P., Saitoh K., Kozlov A., and Robertson B. Neural bases of goal-directed locomotion in vertebrates - An overview. Brain Res. Rev. 57 (2008) 2-12
20. Hanisch U.K. Effects of interleukin-2 and interferons on the nervous system. In: Ader R., Felten D.L., and Cohen N. (Eds). Psychoneuroimmunology. 3rd ed. vol. 1 (2001), Academic Press, San Diego 585-631
21. Hanisch U.K., and Quirion R. Interleukin-2 as a neuroregulatory cytokine. Brain Res. Rev. 21 (1996) 246-284
22. Howell D.C. Statistical Methods for Psychology. 3rd ed. (1992), Duxbury Press, Belmont 338
23. Hwang K., Yoo K.Y., Kim D.W., Lee H.J., Kang H.Y., Lee H.Y., Kang T.C., Choi S.Y., Kim Y.S., and Won M.H. Transient ischemia-induced changes of interleukin-2 and its receptor immunoreactivity and level in the gerbil hippocampal CA1 region. Brain Res. 1106 (2006) 197-204
24. Jensen J., McIntosh A.R., Crawley A.P., Mikulis D.J., Remington G., and Kapur S. Direct activation of the ventral striatum in anticipation of aversive stimuli. Neuron 40 (2003) 1251-1257
25. Kabbaj M., and Akil H. Individual differences in novelty-seeking behavior in rats: a c-fos study. Neuroscience 106 (2001) 535-545
26. Karrenbauer B.D., Müller C., Spanagel R., Huston J.P., Schwarting R.K.W., and Pawlak C.R. Interleukin-2 reduces extracellular cortical serotonin and influences depression- related behaviour in rats. Program No. 478. 2008 Abstract Viewer/Itinerary Planner (2008), Society for Neuroscience, Washington, DC 2008. Online
27. Koh K.B., and Lee B.K. Reduced lymphocyte proliferation and interleukin-2 production in anxiety disorders. Psychosom. Med. 60 (1998) 479-483
28. Koh K.B., and Lee Y. Reduced anxiety level by therapeutic interventions and cell-mediated immunity in panic disorder patients. Psychother. Psychosom. 73 (2004) 286-292
29. Laakso A., Wallius E., Kajander J., Bergman J., Eskola O., Solin O., Ilonen T., Salokangas R.K.R., Syvälahti E., and Hietala J. Personality traits and striatal dopamine synthesis capacity in healthy subjects. Am. J. Psychiatry 160 (2003) 904-910
30. Lacosta S., Merali Z., and Anisman H. Influence of acute and repeated interleukin-2 administration on spatial learning, locomotor activity, exploratory behaviors, and anxiety. Behav. Neurosci. 113 (1999) 1030-1041
31. Lacosta S., Merali Z., and Anisman H. Central monoamine activity following acute and repeated systemic interleukin-2 administration. Neuroimmunomodulation 8 (2000) 83-90
32. Lapchak P.A., Araujo D.M., Quirion R., and Beaudet A. Immunoautoradiographic localization of interleukin 2-like immunoreactivity and interleukin 2 receptors (Tac antigen-like immunoreactivity) in the rat brain. Neuroscience 44 (1991) 173-184
33. Leppanen J.M. Emotional information processing in mood disorders: a review of behavioral and neuroimaging findings. Curr. Opin. Psychiatry 19 (2006) 34-39
34. Lever C., Burton S., and O'Keefe J. Rearing on hind legs, environmental novelty, and the hippocampal formation. Rev. Neurosci. 17 (2006) 111-133
35. Lorberbaum J.P., Kose S., Johnson M.R., Arana G.W., Sullivan L.K., Hamner M.B., Ballenger J.C., Lydiard R.B., Brodrick P.S., Bohning D.E., and George M.S. Neural correlates of speech anticipatory anxiety in generalized social phobia. NeuroReport 15 (2004) 2701-2705
36. Miguelez M., Lacasse M., Kentner A.C., Rizk I., Fouriezos G., and Bielajew C. Short- and long- term effects of interleukin-2 on weight, food intake, and hedonic mechanisms in the rat. Behav. Brain Res. 154 (2004) 311-319
37. Morgane P.J., Galler J.R., and Mokler D.J. A review of systems and networks of the limbic forebrain/limbic midbrain. Prog. Neurobiol. 75 (2005) 143-160
38. Naito Y., Fukata J., Tominaga T., Masui Y., Hirai Y., Murakami N., Tamai S., Mori K., and Imura H. Adrenocorticotropic hormone-releasing activities of interleukins in a homologous in vivo system. Biochem. Biophys. Res. Commun. 164 (1989) 1262-1267
39. Nestler E.J., Barrot M., DiLeone R.J., Eisch A.J., Gold S.J., and Monteggia L.M. Neurobiology of depression. Neuron 34 (2002) 13-25
40. Nisticò G. Communications among central nervous system, neuroendocrine and immune systems: Interleukin-2. Prog Neurosci 40 (1993) 463-475
41. Nisticò G., and De Sarro G. Is interleukin 2 a neuromodulator in the brain?. Trends Neurosci. 14 (1991) 146-150
42. Pauli S., Linthorst A.C.E., and Reul J.M.H.M. Tumour necrosis factor-α and interleukin-2 differentially affect hippocampal serotonergic neurotransmission, behavioural activity, body temperature and hypothalamic-pituitary-adrenocortical axis activity in the rat. Eur. J. Neurosci. 10 (1998) 868-878
43. Pawlak C.R., and Schwarting R.K.W. Object preference and nicotine consumption in rats with high vs. low rearing activity in a novel open field. Pharmacol. Biochem. Behav. 73 (2002) 679-687
44. Pawlak C.R., and Schwarting R.K.W. Striatal microinjections of interleukin-2 and rat behaviour in the elevated plus-maze. Behav. Brain Res. 168 (2006) 339-344
45. Pawlak C.R., Ho Y.J., Schwarting R.K.W., and Bauhofer A. Relationship between striatal levels of interleukin-2 mRNA and plus-maze behaviour in the rat. Neurosci. Lett. 341 (2003) 205-208
46. Pawlak C.R., Schwarting R.K.W., and Bauhofer A. Cytokine mRNA levels in brain and peripheral tissues of the rat: Relationships with plus-maze behaviour. Mol. Brain Res. 137 (2005) 159-165
47. Paxinos G., and Watson C. The Rat Brain in Stereotactic Coordinates. 4th ed. (1998), Academic Press, Sydney
48. Petitto J.M., McCarthy D.B., Rinker C.M., Huang Z., and Getty T. Modulation of behavioral and neurochemical measures of forebrain dopamine function in mice by species-specific interleukin-2. J. Neuroimmunol. 73 (1997) 183-190
49. Petitto J.M., Huang Z., Hartemink D.A., and Beck R. IL-2/15 receptor-beta gene deletion alters neurobehavioral performance. Brain Res. 929 (2002) 218-225
50. Prut L., and Belzung C. The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review. Eur. J. Pharmacol. 463 (2003) 3-33
51. Rapaport M.H., and Stein M.B. Serum cytokine and soluble interleukine-2 receptors in patients with panic disorder. Anxiety 1 (1994) 22-25
52. Reynolds S.M., and Berridge K.C. Positive and negative motivation in nucleus accumbens shell: bivalent rostrocaudal gradients for GABA-elicited eating, taste "liking"/"disliking" reactions, place preference/avoidance, and fear. J. Neurosci. 22 (2002) 7308-7320
53. Schwarting R.K.W., Thiel C.M., Müller C.P., and Huston J.P. Relationship between anxiety and serotonin in the ventral striatum. NeuroReport 9 (1998) 1025-1029
54. Song C., Merali Z., and Anisman H. Variations of nucleus accumbens dopamine and serotonin following systemic interleukin-1, interleukin-2 or interleukin-6 treatment. Neuroscience 88 (1999) 823-836
55. Thiel C.M., Huston J.P., and Schwarting R.K.W. Hippocampal acetylcholine and habituation learning. Neuroscience 85 (1998) 1253-1262
56. Thiel C.M., Müller C.P., Huston J.P., and Schwarting R.K.W. High versus low reactivity to a novel environment: behavioural, pharmacological and neurochemical assessments. Neuroscience 93 (1999) 243-251
57. van den Heuvel O.A., Veltman D.J., Groenewegen H.J., Witter M.P., Merkelbach J., Cath D.C., van Balkom A.J.L.M., van Oppen P., and van Dyck R. Disorder-specific neuroanatomical correlates of attentional bias in obsessive-compulsive disorder, panic disorder, and hypochondriasis. Arch. Gen. Psychiatry 62 (2005) 922-933
58. Waldmann T.A. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat. Rev. Immunol. 6 (2006) 595-601
59. Walker L.G., Walker M.B., Heys S.D., Lolley J., Wesnes K., and Eremin O. The psychological and psychiatric effects of rIL-2 therapy: a controlled clinical trial. Psycho-Oncology 6 (1997) 290-301
60. Wichers M., and Maes M. The psychoneuroimmuno-pathophysiology of cytokine-induced depression in humans. Int. J. Neuropsychopharmacol. 5 (2002) 375-388
61. Wilcox R.R. New designs in analysis of variance. Annu. Rev. Psychol. 38 (1987) 29-60
62. Zalcman S.S. Interleukin-2 potentiates novelty- and GBR 12909-induced exploratory activity. Brain Res. 899 (2001) 1-9
63. Zalcman S.S., and Siegel A. The neurobiology of aggression and rage: role of cytokines. Brain Behav. Immun. 20 (2006) 507-514
64. Zalcman S.S., Green-Johnson J.M., Murray L., Nance D.M., Dyck D., Anisman H., and Greenberg A.H. Cytokine-specific central monoamine alterations induced by interleukin-1, -2 and -6. Brain Res. 643 (1994) 40-49
65. Zalcman S., Murray L., Dyck D.G., Greenberg A.H., and Nance D.M. Interleukin-2 and -6 induce behavioral-activating effects in mice. Brain Res. 811 (1998) 111-121